TickerFacts.

Nexgel, Inc. (NXGL): Long-Term Debt

Annual figures by period end, from SEC filings.

$588.0K
As of 2025-12-31
+27.6%
3-year compound annual growth
$685.0K2022-12-31: $283.0K2023-12-31: $593.0K2024-12-31: $685.0K2025-12-31: $588.0K$588.0K
2022-12-31 Long-Term Debt (USD) 2025-12-31
Period endedLong-Term DebtChange YoYSource filing
2025-12-31$588.0K-14.2%2026-03-31, Balance as of period end
2024-12-31$685.0K+15.5%2025-03-27, Balance as of period end
2023-12-31$593.0K+109.5%2024-04-10, Balance as of period end
2022-12-31$283.0Kn/a2023-03-28, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (Surgical & Medical Instruments & Apparatus), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedLong-Term DebtChange YoY
Nexgel, Inc. (NXGL)2025-12-31$588.0K-14.2%
Profound Medical Corp. (PROF)2025-12-31$4.50M-3.5%
Vivos Therapeutics, Inc. (VVOS)2025-12-31$753.0Kn/a
INVO Fertility, Inc. (IVF)2025-12-31$892.5Kn/a
Spectral AI, Inc. (MDAI)2025-12-31$9.25Mn/a
Baird Medical Investment Holdings Ltd (BDMD)2025-12-31$8.72M+96.0%
Premier Air Charter Holdings Inc. (PREM)2025-12-31$485.7Kn/a
Orchestra BioMed Holdings, Inc. (OBIO)2025-12-31$15.00M0.0%
ClearPoint Neuro, Inc. (CLPT)2025-12-31$49.08Mn/a

Compare NXGL, PROF, VVOS, IVF side by side · Screen every company in Surgical & Medical Instruments & Apparatus ↗